BBC Valuation

Virtus LifeSci Biotech Clinical Trials ETF (BBC) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is between -- to -- according to relative valuation method.

BBC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is between -- to -- according to relative valuation method.

The average P/S ratio for BBC's competitors is 0.00, providing a benchmark for relative valuation. Virtus LifeSci Biotech Clinical Trials ETF Corp (BBC) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

As of Mar 04 2026, Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a P/B ratio of NaN. This indicates that the market values BBC at NaN times its book value.

As of Mar 04 2026, Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a FCF Yield of NaN%. This means that for every dollar of Virtus LifeSci Biotech Clinical Trials ETF's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 04 2026, Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Virtus LifeSci Biotech Clinical Trials ETF's expected earnings over the next 12 months.

As of Mar 04 2026, Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a Forward P/S ratio of NaN. This means the market is valuing BBC at $NaN for every dollar of expected revenue over the next 12 months.